The effects of nasal decongestion on obstructive sleep apnoea.
Nasal decongestion
Nasal obstruction
Obstructive sleep apnoea
Polysomnography
Sleep disorder
Journal
American journal of otolaryngology
ISSN: 1532-818X
Titre abrégé: Am J Otolaryngol
Pays: United States
ID NLM: 8000029
Informations de publication
Date de publication:
Historique:
received:
11
08
2018
accepted:
20
08
2018
pubmed:
24
9
2018
medline:
4
4
2019
entrez:
24
9
2018
Statut:
ppublish
Résumé
Many studies have indicated associations between impaired nasal breathing and sleep disorders. However, the precise nature of the relationship between nasal patency and sleep remains unclear. We analysed the effects of nasal patency on sleep architecture and breath in nasal obstruction-predominant obstructive sleep apnoea (NO-OSA) patients by applying nasal decongestant. A randomized, placebo-controlled double-blind crossover study was performed in OSA patients with chronic nasal obstruction and without obvious pharyngeal narrowing. All OSA patients (confirmed by polysomnography) were recruited and completed 2 overnight studies (randomly applying oxymetazoline or placebo). Data collected after oxymetazoline or placebo treatments were compared. The ClinicalTrials.gov identifier is NCT03506178. Compared with placebo, oxymetazoline resulted in significant increase in rapid eye movement sleep (p = 0.027) and reduction of stage 1 sleep (p = 0.004), as well as arousal index (p = 0.002). Moreover, great improvements in apnoea/hypopnea index (AHI) were observed (p < 0.001); AHI in the supine position was significantly reduced (p = 0.001). Oxygen saturation during sleep was increased significantly [mean oxygen saturation (p = 0.005) and lowest oxygen saturation (p = 0.024)]. Oxygen desaturation index was significantly reduced (p < 0.001). Improving nasal patency by decongestant could improve sleep quality, AHI, and oxygen saturation level during sleep.
Sections du résumé
BACKGROUND
BACKGROUND
Many studies have indicated associations between impaired nasal breathing and sleep disorders. However, the precise nature of the relationship between nasal patency and sleep remains unclear.
PURPOSE
OBJECTIVE
We analysed the effects of nasal patency on sleep architecture and breath in nasal obstruction-predominant obstructive sleep apnoea (NO-OSA) patients by applying nasal decongestant.
MATERIAL AND METHODS
METHODS
A randomized, placebo-controlled double-blind crossover study was performed in OSA patients with chronic nasal obstruction and without obvious pharyngeal narrowing. All OSA patients (confirmed by polysomnography) were recruited and completed 2 overnight studies (randomly applying oxymetazoline or placebo). Data collected after oxymetazoline or placebo treatments were compared. The ClinicalTrials.gov identifier is NCT03506178.
RESULTS
RESULTS
Compared with placebo, oxymetazoline resulted in significant increase in rapid eye movement sleep (p = 0.027) and reduction of stage 1 sleep (p = 0.004), as well as arousal index (p = 0.002). Moreover, great improvements in apnoea/hypopnea index (AHI) were observed (p < 0.001); AHI in the supine position was significantly reduced (p = 0.001). Oxygen saturation during sleep was increased significantly [mean oxygen saturation (p = 0.005) and lowest oxygen saturation (p = 0.024)]. Oxygen desaturation index was significantly reduced (p < 0.001).
CONCLUSIONS
CONCLUSIONS
Improving nasal patency by decongestant could improve sleep quality, AHI, and oxygen saturation level during sleep.
Identifiants
pubmed: 30243839
pii: S0196-0709(18)30757-9
doi: 10.1016/j.amjoto.2018.08.003
pii:
doi:
Substances chimiques
Nasal Decongestants
0
Oxymetazoline
8VLN5B44ZY
Banques de données
ClinicalTrials.gov
['NCT03506178']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-56Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.